Clinical Trial Update: Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of everolimus (RAD001) and erlotinib for recurrent head and neck squamous cell carcinoma has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• Tarceva (erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head And Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-04